Encapsulated Probiotic Microorganisms in Functional Food Products

Q4 Biochemistry, Genetics and Molecular Biology Mikrobiolohichnyi zhurnal Pub Date : 2023-12-21 DOI:10.15407/microbiolj85.06.077
S. Starovoitova, K. Kishko, O.M. Demchenko, V.V. Bila
{"title":"Encapsulated Probiotic Microorganisms in Functional Food Products","authors":"S. Starovoitova, K. Kishko, O.M. Demchenko, V.V. Bila","doi":"10.15407/microbiolj85.06.077","DOIUrl":null,"url":null,"abstract":"Alterations in the composition of the gut microbiota are associated with a wide range of pathologies, including not only inflammatory diseases of the gastrointestinal tract, but also diabetes, obesity, cancer, and diseases of the cardiovascular and central nervous systems. With an imbalance of the microbiota (dysbiosis), there is increased intestinal permeability and a violation of local or systemic immune responses. One of the possible ways to improve intestinal microbiota is the use of dietary supplements and functional food products enriched with highly effective encapsulated probiotic microorganisms, as well as prebiotic compounds. Such products contribute to the restoration of normal intestinal microflora and its integrity, and also indirectly affect the positive outcome in the treatment of many pathological conditions mediated by an imbalance in the intestinal microbiota. Maintaining the activity of probiotics in food carriers or functional food products designed for the prevention and complex therapy of various pathological conditions is important both for the normalization of the intestinal microflora and the health of the body as a whole. In this context, encapsulation is an effective approach to maintain the viability and stability of probiotics under adverse conditions in the gastrointestinal tract and also an effective way to protect from processing conditions, temperature, and transportation. The development of functional nutrition products enriched with highly effective encapsulated probiotic microorganisms is a priority for new research in the field of prevention and treatment in microbiota-targeted therapy. The use of such products is based on the conception of 3p — pathophysiology-based individualized use of probiotics and prebiotics in various pathological conditions mediated by a violation of the qualitative and/or quantitative composition of the intestinal microbiota: implementing a predictive, preventive, and personalized medical approach.","PeriodicalId":18628,"journal":{"name":"Mikrobiolohichnyi zhurnal","volume":"3 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mikrobiolohichnyi zhurnal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15407/microbiolj85.06.077","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

Alterations in the composition of the gut microbiota are associated with a wide range of pathologies, including not only inflammatory diseases of the gastrointestinal tract, but also diabetes, obesity, cancer, and diseases of the cardiovascular and central nervous systems. With an imbalance of the microbiota (dysbiosis), there is increased intestinal permeability and a violation of local or systemic immune responses. One of the possible ways to improve intestinal microbiota is the use of dietary supplements and functional food products enriched with highly effective encapsulated probiotic microorganisms, as well as prebiotic compounds. Such products contribute to the restoration of normal intestinal microflora and its integrity, and also indirectly affect the positive outcome in the treatment of many pathological conditions mediated by an imbalance in the intestinal microbiota. Maintaining the activity of probiotics in food carriers or functional food products designed for the prevention and complex therapy of various pathological conditions is important both for the normalization of the intestinal microflora and the health of the body as a whole. In this context, encapsulation is an effective approach to maintain the viability and stability of probiotics under adverse conditions in the gastrointestinal tract and also an effective way to protect from processing conditions, temperature, and transportation. The development of functional nutrition products enriched with highly effective encapsulated probiotic microorganisms is a priority for new research in the field of prevention and treatment in microbiota-targeted therapy. The use of such products is based on the conception of 3p — pathophysiology-based individualized use of probiotics and prebiotics in various pathological conditions mediated by a violation of the qualitative and/or quantitative composition of the intestinal microbiota: implementing a predictive, preventive, and personalized medical approach.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
功能性食品中的封装益生微生物
肠道微生物群组成的改变与多种病症有关,不仅包括胃肠道炎症,还包括糖尿病、肥胖症、癌症以及心血管和中枢神经系统疾病。微生物群失衡(菌群失调)会导致肠道渗透性增加,局部或全身免疫反应紊乱。改善肠道微生物群的可行方法之一是使用富含高效胶囊益生微生物和益生化合物的膳食补充剂和功能性食品。这类产品有助于恢复正常的肠道微生物区系及其完整性,还能间接影响由肠道微生物区系失衡引起的多种病理情况的治疗效果。在用于预防和综合治疗各种病症的食品载体或功能食品中保持益生菌的活性,对于肠道微生物区系的正常化和整个人体的健康都非常重要。在这种情况下,封装是在胃肠道不利条件下保持益生菌活力和稳定性的有效方法,也是保护益生菌不受加工条件、温度和运输影响的有效途径。开发富含高效封装益生微生物的功能性营养产品是微生物群靶向疗法预防和治疗领域新研究的重点。这类产品的使用基于 3p 概念--基于病理生理学的益生菌和益生元的个性化使用,适用于由肠道微生物群的定性和/或定量组成失调引起的各种病理情况:实施预测、预防和个性化医疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Mikrobiolohichnyi zhurnal
Mikrobiolohichnyi zhurnal Medicine-Microbiology (medical)
CiteScore
0.70
自引率
0.00%
发文量
0
期刊最新文献
Гуанідінійвмісний олігомер як інгібітор мікробної корозії металу Xanthomonas fuscans subsp. fuscans — a Pathogen of Small Brown Spot of Legumes Роль бактерій як основи пелагічних харчових ланцюгів в ультраоліготрофних північних патагонських озерах: міні-огляд Phenotypic and Genotypic Criteria for the Screening of Highly Active S-Type Pyocins Pseudomonas aeruginosa Producers Характеристика генів інтегронів клінічних ізолятів Pseudomonas aeruginosa, які реалізують резистентність до антибіотиків та біоплівкоутворення цими штамами
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1